Monday, February 06, 2023 9:28:47 PM
This is what is agreed upon:
Reformulated Patent Pending SequestOx™ is the SAFEST IR Opioid in the World.
It will easily receive Oral (chewing) Abuse Deterrent Labeling like no other IR ADF Opioid has.
Here’s how it works:
FDA validated the entire ER ADF line of ELTP 2 bead antagonist ADF tech works. It works very well, and it will also work very well for any opioid agonist with any time-release. Below is the ELI-200 nasal abuse HAL study. Recreational users thought ELI-200 (blue line) was same as placebo (red and yellow lines). Actually, they initially disliked it, and they never started liking it. The blue line never rises above placebo throughout the duration of the test. No doubt the antagonist bead works great. (The agonist bead is supposed to be the easy part.)
FDA did not find one issue with Elite 2 bead ADF except for fed Tmax which only applies to IR opioids.
Not one issue with HAL studies.
Quote:
"the FDA made no comment about Elite’s technology because it works and it’s solid. They made no comment on the human abuse liability studies because again they were solid and they work; or with the withdrawal study or the efficacy study – the Bunionectomy. This is great news for Elite’s ADT platform. There is no effect on Elite’s ER formulations"
ELTP 2 bead antagonist ADF tech works. It works very well, and it will also work very well for any opioid agonist with any time-release. Below is the ELI-200 nasal abuse HAL study. Recreational users thought ELI-200 (blue line) was same as placebo (red and yellow lines). Actually, they initially disliked it, and they never started liking it. The blue line never rises above placebo throughout the duration of the test. No doubt the antagonist bead works great. (The agonist bead is supposed to be the easy part.)
Recent Pilot study for Re-formulated SequestOx validated entire lineup of IR ADFs Now Elite's tech can be used on all IR opioids
Pilot Study: shows a positive FedTmax for SequestOx which was the ONLY ISSUE with the IR ADF lineup.
http://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=86991&BzID=2258&g=939&Nav=0&LangID=1&s=0
ELITE PHARMA
ELTP
rma.com/wp-content/uploads/2014/12/How_It_Works.jpg[/img]
Q The only issue with SequestOx™ was the FedTmax.
That was fixed months ago the PR was early this year.
See below for supporting link and exceptional results.
Quote:
“We resolved that issue and our patent attorney, Dr. Smith determined that this is something patentable and we will be filing a patent sometime next week.”
IR SequestOx™ will establish a New Standard of Care 2020-2021.
The most frequently abused opioids are currently immediate-release (IR) opioids.
In 2016 93% of new opiod RXs were for IR(Immediate Release) opiods.
Reformulated SequestOx™ with lowered fed Tmax is the SAFEST Immediate Release opiod in the world, and the only one using a Pharmalogical Approach to abuse deterrence.
According to data from “Do abuse deterrent opioid formulations work?” Richard C. Dart, MD, PhD; Janetta L. Iwanicki, MD; Nabarun Dasgupta, PhD; Theodore J. Cicero, PhD; Sidney H. Schnoll, MD, PhD, in the Journal of Opioid Management 13:6, November/December 2017, reported that Immediate Release (IR) opioids are 4.6 times more likely to be intentionally abused and 6.1 times more likely to be diverted than Extended Release (ER) formulations. Not surprisingly, cited in the aforementioned work is a real-world study of 300 opioid abusers entering treatment for substance abuse who indicated they prefer abusable IR opioid products because they provide faster onset of the rewarding effects.
SequestOx™.
HammerBottom is in the rear view back under 3¢
$$$ starting to roll in
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM